Affordable Access

The synthesis of 191Pt labelled JM216, an orally active platinum anti-tumour agent.

Authors
  • Bates, P I
  • Sharma, H L
  • Murrer, B A
  • Bernard, C F
  • McAuliffe, C A
Type
Published Article
Journal
Applied Radiation and Isotopes
Publisher
Elsevier
Publication Date
Apr 01, 1997
Volume
48
Issue
4
Pages
469–476
Identifiers
PMID: 9106988
Source
Medline
License
Unknown

Abstract

The orally active platinum anti-tumour complex JM216[bis-acetatoamminedichlorocyclohexylamineplatinum(IV)] is at present in stage II clinical trials. A procedure for synthesising the complex labelled with 191Pt or 188Pt at the platinum centre has been developed. The purity (shown by HPLC) is 98% and the specific activity (0.3-0.4 Ci/kg) is enough for in vivo and in vitro studies.

Report this publication

Statistics

Seen <100 times